Medical M&A Surge: Multiple Companies Announce Equity Acquisitions This Week

　　【Pharmaceutical Network - Industry Trends] This week (June 22–26), multiple companies in the healthcare and related sectors announced equity acquisition deals, involving INT Medical, Medprin, and Aipu Shares, among others. The primary drivers for these acquisitions were expansion into high-growth segments and synergy across upstream and downstream parts of the industry chain to build “closed-loop” capabilities.
 

Recent news indicates that Medprin’s share issuance for asset acquisition will be submitted to the Mergers and Acquisitions and Restructuring Review Committee of the Shenzhen Stock Exchange for deliberation on June 26, 2026. The company plans to acquire 100% equity interest in Guangzhou Yijie Medical Technology Co., Ltd. from ten counterparties, including Guangzhou Zexin Medical Technology Co., Ltd., through a combination of share issuance and cash payment, at a transaction price of approximately RMB 335 million.
 

Public information indicates that Medprin is a Chinese enterprise specializing in high-performance implantable medical devices for neurosurgery, with product lines including artificial dural (spinal) membrane patches, craniomaxillofacial repair and fixation systems, absorbable regenerated oxidized cellulose, and dural sealants. In 2025, the company’s revenue reached approximately RMB 369 million, representing a year-on-year increase of 32.46%; net profit attributable to shareholders amounted to approximately RMB 113 million, a year-on-year increase of 43.47%. Yijie Medical primarily engages in the research and development, manufacturing, and sales of endovascular interventional medical devices for neurology and neurosurgery, with its pipeline projects covering access, ischemic, and hemorrhagic product categories. The company reported continuous net losses from 2023 through the first eleven months of 2025, with net profits of -RMB 28.1191 million, -RMB 22.6685 million, and -RMB 12.4496 million, respectively.
 

On June 25, INT Medical issued an announcement regarding a disclosable transaction, proposing the conditional acquisition of approximately 0.79% equity interest in Valgen Holding Corporation. The announcement stated that the company intends to acquire 119,545 shares of Series B Preferred Stock from the seller, representing approximately 0.79% of the total issued share capital of the target company, for a total consideration of USD 10 million. The target company holds 100% equity interest in Valgen Medtech. According to available information, Valgen Medtech is primarily engaged in the research and development, manufacturing, and sales of interventional therapy technologies and products for atrioventricular valve diseases.
 

On the same day, INT Medical also announced that the company plans to acquire a total of 35% equity in Pulin Medical. With March 31, 2026 as the base date, the assessed value of all shareholders' equity in Pulin Medical was RMB 89.3869 million.
 

On June 25, ST Haiwang issued an announcement stating that its controlling subsidiary, Shenzhen Neptunus Interlong Biotech Co., Ltd., intended to sign an “Letter of Intent for Investment” with Jinbaihui on June 25, 2026, to acquire a portion of its equity through either a private placement or the transfer of existing shares. It is reported that Neptunus Interlong is primarily engaged in the research and development, manufacturing, and sales of pharmaceuticals and medical devices, with its product portfolio covering multiple therapeutic areas including oncology, cardiovascular system, respiratory system, digestive system, and mental disorders. Jinbaihui Bio focuses on early diagnosis and screening of cancer, possessing a miRNA technology platform and domestic colorectal cancer detection products based on this technology.
 

This transaction represents a significant move by ST Haiwang to strengthen its pharmaceutical manufacturing segment, helping the company extend its industrial chain, expand into early cancer screening and in vitro diagnostics businesses, enrich its product pipeline, cultivate new growth drivers, and enhance overall market competitiveness.
 

On June 23, Aipu Shares announced that the company, through its wholly-owned subsidiary Shanghai Aipu Dingchun Life Technology Co., Ltd., would acquire 100% equity interest in Nuoya Shengnuo (Taicang) Biotechnology Co., Ltd. for a total cash consideration of RMB 450 million. The transaction will be conducted in two tranches.
 

Noah Shengnuo is a manufacturer of Omega-3 raw materials, with products including refined fish oil and concentrated fish oil. Its downstream applications span the health supplements, functional food and beverage, infant nutrition, and pet food sectors. On December 9, 2024, Xinhua Pharmaceutical signed an “Intent Agreement for Equity Acquisition” with Noah Shengnuo Europe, proposing to acquire no more than 75% of Noah Shengnuo’s equity. However, on February 6, 2026, Xinhua Pharmaceutical terminated the intent agreement due to “failure to reach a mutual agreement between the parties.”
 

　　……
 

Overall, although these transactions vary in scale and rationale, they collectively reflect the development trends in the pharmaceutical and healthcare industry, driven by two forces: horizontal expansion into high-growth sectors and vertical integration of the upstream and downstream segments of the industrial chain. In the future, with the rapid development of the healthcare industry, mergers and acquisitions among enterprises are expected to become increasingly frequent.
 

　　Disclaimer: Under no circumstances shall the information contained herein or the opinions expressed constitute investment advice to any person.